I have completed a internship in Brand Awareness and sale in company 1MG and also financial analysis of two Business of the Pharmaceutical industry.

1. Corporate Internship
Topic- Brand Awareness and Sale
Company- 1MG
BY
NAME- SHASHANK SINGH
ENROLMENT NO-19609034
25/07/2020

2. INTRODUCTION
 Internship program is the program in which companies here college students for particular
project.
 It help student as they get chance to work in an organization and it also make their resume
strong as it work as an experience for freshers.
 The main purpose of internship program is to give students experience good exposure to
corporate world and students will get to know how organization works
 There are various purpose of internship program some are written under as
a) Exposure of corporate world.
b) Getting experience in particular field
c) To know more about market condition and corporate working.
d) To analyse the knowledge of the job responsibility

3. COMPANY PROFILE
 1mg is a company that operates a consumer health platform.
 Prashant Tandon, CEO and founder of 1mg.
 Online pharmacy network and generic medicine engine based in Gurgaon, Haryana.
 India’s largest and best consumer health platform
 Started as HealthKartPlus a medical information repository(now a nutrition brand).
 It was founded in 2015.
 Recognized by Government of India- Ministry of Health & Family welfare as health initiative.

4. DETAILS OF BUSINESS
 Booking diagnostic tests with online report facility
 Booking appointment with best doctors online
 They reminder to take medicine on time(1mg med Remined)
 Online consultation chat bots for instantaneous aid
 Regular Health tips(1mg Capsules)
 Assistance in finding the doctors by providing their entire profile, review ,rating(1mg).

5. INDUSTRY ANALYSIS
 Market Size and Growth Trends
I. The total value of pharmaceutical industry in India was about 32 billion in 2017 and generic
drug for 20 percent of global exports in terms of volume.
II. Pharmaceutical market turnover reached Rs 1.4 lakh crore in 2019, growing 9.8 % year on
year from Rs 129,015 crore in 2018
III. Pharmaceutical export includes bulk drugs, intermediates, drug formulations, biologicals,
Ayush & herbal product surgical.
IV. India companies have received 304 Abbreviated New Drug Application (ANDA) approvals
from the US Food and Drug Administration (USFDA) in 2017
V. They have also received a total of 415 product approvals in 2018 and 73 tentative approvals
VI. The compound annual growth rate (CAGR) is 10 %.

6.  INVESTMENTS
The Department for Promotion of Industry and Internal Trade (DPIIT) drugs and
pharmaceuticals sector attracted cumulative FDI inflows worth US$ 16.25 billion
between April 2000 and June 2019.
Some of the major investments:
 During December 2018-19, the moving annual total (MAT), industry growth was 9.8
percent, with price growth at 5.3 percent.
 Healthcare sector witness’s private equity of total US$ 1.1 billion with 27 deals in
first half of year 2019.
 The exports of India pharmaceutical industry to the US will raise as a branded drug
worth US$ 55 billion will become off patent during 2017-2018.
 On October 2019, Telangana government proposed Hyderabad Pharmacy with
financial assistance from Central government of US$ 489 million.

7. Source : Department of Industrial Policy & Promotion,
Office of the Economic Advisor, TechSci Research
104.8
107.2
113.2
117.7
119.4
121
122.3
I NDEX
PRODUCTION OF PHARMACEUTICAL(MILLION TONNES)
FY12 FY13 FY14 FY15 FY16 FY17 FY18

8.  GOVERNMENT INTIATIVES
 Government has been allocated to health insurance scheme Ayushman Bharat- Pradhan
Mantri Jan Arogya Yojana (AB-PMJAY) at Rs 6,400 crore.
 In Budget 2020-21, Government of India announced allocation to the Ministry of Health and
family Welfare is Rs 65,012 crore (US$ 9.30 billion). Also the government has allocated Rs
34,115 crore (US$ 4.88 billion) towards the National Health Mission under which rural and
urban will get the benefited.

9.  ROAD AHEAD
 In next five year, the medicine spending in India is project to grow 9-12 percent leading India
to become one of the top 10 countries in terms of medicine spending.
 Indian government has taken many steps to reduce more costs and bring down healthcare
expenses.
Major Players in the Pharmaceutical Industry
 Sun Pharma (15.13%)
 Cipla (4.83%)
 Dr. Reddy’s (0.48%)

10.  COMPETITIVE ANALYSIS
The growth of the market is product innovation and differentiation leading to
premiumization. Factor such as availability of product, advanced technology, innovative
development in products are leading to increased sale of medicine. One of the major keys
to success is give different type of medicine.
There are many types of medicine are currently available in India market right now –
 Antipyretics: (Reducing Fever)
 Analgesic: (Reducing Pain)
 Antimalarial Drug: (Treating Malaria)
 Antibiotics: (Inhibiting germ growth)
 Antiseptics: (Burn in hand, Cut)

11.  Patents:
Every successful company in pharmaceutical industry has its own patent assigned and thus mark
as a goodwill to it. Pharmaceutical is being the most growing industry in the market and will go
more and more in the upcoming year so. If I talk about the scope of this business, then it is way
too wide. But thus, if the scope is a large then the number of players do increase and to maintain
with the competition different schemes are being used by different companies.
 BARRIERS TO ENTRY
Pharma industry is one of the most easily accessible industries for an entrepreneur in India. The
capital requirement for the industry is low, creating a regional.
Creating brand awareness amongst doctors is the key for long-term survival. Also, quality
regulations by the government may put some barrier for establishing new manufacturing
operations

12.  PERFECT SUBSTITUTION
Pharmaceutical have a great advantage of the pharma industry. Whatever happen, demand for
pharma products continues and the industry develop. The reason for high competitiveness in the
industry is that as an ongoing concern, pharma industry seems to have an infinite future.
PRODUCT DEVELOPMENT
Companies are also starting to change their product development processes to the new
environment. firms have made their ways into the market by researching generic competitors to
patented drugs and following up with litigation to challenge the patent.

13. THE 4P’S OF PHARMACEUTICAL INDUSTRY
 PRICE:
Most of the companies in the pharmaceutical industry set in the uniquely price. The
producer or manufacturer is in a control of price, subject to normal market constraints
 PRODUCT
All medications on the market are FDA indicated for a specific condition or disease, and
pharmaceutical companies can only market a product for the approved indication(s).
 PROMOTION
Promotion of pharmaceuticals to professionals has experienced to shift with the
development of nonpersonal selling techniques. Doctors are utilizing more external sources
for information about products and bypassing the traditional representative
 PLACE
The distribution system of getting a medication from point A (manufactured) to point
B (pharmacy/end-user) has remained relatively the same over the years via the role of
the wholesaler, community pharmacies and, more recently, mail order pharmacies.

14. SWOT ANALYSIS
 Strengths
 Cost competitiveness
 Developed Industry with strong manufacturing Base
 Weakness
 Low investments in innovative R&D.
 Low medical and healthcare expenditure in the country
 Opportunities
 Potential for developing India as a centre for international clinical trails
 Contract manufacturing arrangement with MNC.
 Threats
 Drug price control order puts unrealistic ceilings on product prices and profitability
 Product patent regime poses serious challenge to domestic industry unless it invests in
research and development

15. FINANCIAL ANALYSIS
 Liquidity Ratio
I. Current Ratio
 Interpretation-In Dr. Reddy’s, the current ratio increased from 1.91 in year 2017-18 to 2.90 in year 2018-19. In Sun
pharmaceutical increased from 0.76 in year 2017-18 to 0.84 in year 2018-19. Since measure of efficiency, therefore higher
ratio is better it is. Here, clearly Dr. Reddy’s is better than Sun pharma has its higher ratio.
YEAR DR.
RDDY’S
SUN
PHARMA
2017-18 1.91 0.76
2018-19 2.9 0.84
0
1
2
3
4
DR.RDDY'S SUN PHARMA
Current ratio
2017-18 2018-19
.

16.  Quick Ratio
 Interpretation-For Dr.Reddy’s quick ratio was 1.52 in 2017-18 and 2.25 in 2018-19. Its is good
that its increased. And while Sun pharma was 0.59 in 2017-18 and 0.63 in 2018-19. So thereby,
Dr. Reddy has a capacity to pay current liabilities without selling inventory.
YEAR DR. REDDY’S SUN PHARMA
2017-18 1.52 0.59
2018-19 2.25 0.63
0
0.5
1
1.5
2
2.5
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2018-19

17.  Profitability Ratio
I. Return on sale
Interpretation- Return on Sale for Dr.Reddy’s is 0.06 in 2017-18 and now its 0.12 in 2018-19
its measure less profit in being produced for sales. Whereas, Sun pharmaceutical has increased
company growth more efficiently is 2.60 in 2017-18 and 2.90 in the year 2018-19.
YEAR DR.REDDY'S SUN PHARMA
2017-18 0.06 2.6
2018-19 0.12 2.9
0
0.5
1
1.5
2
2.5
3
3.5
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2018-19

18.  Asset Turnover Ratio
 Interpretation-For Dr.Reddy’s asset turn turnover ratio is increases to efficiently employ its assets to
generate sale from 1.03 in year 2017-18 to 1.12 in 2018-19. Whereas, Sun pharma failing to efficiently
employ its assets to generate sales.
YEAR DR.REDDY'S SUN PHARMA
2017-18 1.03 2.97
2018-19 1.12 2.41
0
0.5
1
1.5
2
2.5
3
3.5
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2018-19

19.  Leverage Ratio
I. Equity Ratio
Interpretation-Equity ratio for Dr.Reddy’s is 0.93 in 2017-18 and 0.96 in 2018-19,
Similar for Sun Pharma is 0.79 in 2017-18 and 0.80 in 2018-19 both companies
generally indicates less risk and better financial strength that a lower ratio
YEAR DR.REDDY'S SUN PHARMA
2017-18 0.93 0.79
2018-19 0.96 0.8 0
0.2
0.4
0.6
0.8
1
1.2
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2018-19

20.  Debt Equity Ratio
Interpretation- In Dr.Reddy’s the debt equity ratio has decreased from 0.22 in year 2017-18
to 0.08 in year 2018-19, Similarly for Sun pharma has decreased from 0.79 in year 2017-18 to 0.80
in year 2018-19 its means both companies assets are more funded by equity.
YEAR DR.REDDY'S SUN PHARMA
2017-18 0.22 0.31
2018-19 0.08 0.28
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2018-19

21.  Market Related Ratio
1. Return On Equity
Interpretation- Return on Equity for Dr.Reddy’s is 4.88 in year 2017-18 to 10.50 in
year 2018-19 its increased its profit and therefore return on equity, whereas for Sun
pharma is 1.41 in year 2017-18 to 3.62 in year 2018-19 it’s also increase their profit
YEAR DR.REDDY'
S
SUN PHARMA
2017-18 4.88 1.41
2018-19 10.5 3.62
0
2
4
6
8
10
12
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2017-18

22.  Earning Per Share
 Interpretation-This ratio implies that profit is divided amongst shareholder. So, for
Dr.Reddy’s it was 34.15 in 2017-18 which means profit to shareholders which came out
to be 76.95 in 2018-19, whereas in case of Sun pharma which means less shareholders
which is 1.27 in 2017-18 to 3.4 in 2018-19.
YEAR DR.REDDY'S SUN PHARMA
2017-18 34.15 1.27
2018-19 76.95 3.4
0
10
20
30
40
50
60
70
80
90
DR.REDDY'S SUN PHARMA
Chart Title
2017-18 2017-18

23. PROJECT DETAILS
Objective of Report
 To discover reasonable innovation through an extensive glance at different stage
advancements for the pharmaceutical.
 To find out competitors in pharmaceutical market.
 To centre around worldwide industry improvement through an inside and out investigation of
the significant world markets for pharmaceutical assembling.
 To build up the basics of the Indian pharmaceutical market including definition, procedure
and patterns.

24.  Project Analysis
 Market sale
 Interpretation-The sale of medicine it clear that market is led by Aurobindo Pharma as consistent growth over
a year. There is a key which Aurobindo Pharma very well is that they made the availability of their product very
fast. Cipla have very close sale of the market and its price very competitively
Aurobindo
pharma
13,266
Cipla 12659
Lupin 11850
Glenmark 6712
Alkem lab 6677
Torrent pharm 6168
Divis labs 5310
Ipca labs 4367
13,266
12659
11850
6712 6677
6168
5310
4367
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
Aurobindo
pharma
cipla Lupin Glenmark Alkem lab Torrent
pharm
Divis labs Ipca labs
Chart Title

25.  Project Goal
Explicit:
 Well characterized
 Anyone that has an essential information on the task
Quantifiable
 Know if the objective is gotten and the distance away consummation
 Find out when accomplished your objective
Settled upon
 Agreement with all the stakeholders what the goal should be Realistic
 Within the availability of resource, knowledge and also the time
Time -based
 Enough time to accomplish the objective
 There is not lot of time which can affect project performance

26. KEY LEARNING
 Patience- is the key to success; one should be patient and thus handle things very calmly. In a
market no one should burst out of anger for no reason and if they are in a situation where they are
getting impatient, they should give themselves a break and need to handle things in a nice manner.
 I learned that no one going to come and help me through things. There will be no spoon feeding
you have to do your work on your own I should stand for myself if I want to learn anything.
 This project made my excel skills strong as all the data which I collected must be smutted in a
master sheet and this project also include the presentation in the end which force me to work on
my presentation skills.
 The main thing in any organizing is the work ethics everyone must work under the work ethics.
 Time management, timing is the key to success, there are deadlines which you must follow,
completing your work in time are important.
 As I have to work in a market a proper and clear communication is very important, in market you
find various kind of people some may entertain you some may not but it’s all upon you how you
interact with them to get more information.

27. CONCLUSION
 The Pharmaceutical market is profoundly serious and stays commanded by low evaluated,
locally created generics. In term of significant worth the India represents under 2% of the
world market and per capita use on pharmaceuticals is moderately low.
 The sector has huge potential to grow with more players entering the sector be possibilities of
healthy completion
 Aurobindo Pharma, Lupin and Cipla have strong fundamentals and are strong players in the
industry, it is increasing sale as faster rate. Aurobindo Pharma has the highest net sale in India.
 1mg gives the patients regular health tips and let them order medicine online, book lab test
and package from certified labs near them.